Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · IEX Real-Time Price · USD
1.770
+0.100 (5.99%)
At close: Apr 19, 2024, 4:00 PM
1.680
-0.090 (-5.08%)
After-hours: Apr 19, 2024, 7:56 PM EDT
Cardiol Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CRDL stock have an average target of 4.50, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 154.24% from the current stock price of 1.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 14, 2023.
Analyst Ratings
The average analyst rating for CRDL stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $3 | Buy | Reiterates | $3 | +69.49% | Aug 14, 2023 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $5 → $6 | Strong Buy | Maintains | $5 → $6 | +238.98% | May 19, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 17, 2021 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 3, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.44
from -0.44
EPS Next Year
-0.40
from -0.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 17.5M | 124.6M | 244.4M |
| Avg | n/a | n/a | 8.5M | 77.1M | 172.1M |
| Low | n/a | n/a | n/a | 31.8M | 102.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,363.0% | 217.1% |
| Avg | - | - | - | 804.8% | 123.4% |
| Low | - | - | - | 273.2% | 33.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.37 | -0.27 | -0.37 | 0.13 | 0.76 |
| Avg | -0.44 | -0.40 | -0.37 | 0.12 | 0.74 |
| Low | -0.51 | -0.53 | -0.36 | 0.12 | 0.71 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 517.5% |
| Avg | - | - | - | - | 499.8% |
| Low | - | - | - | - | 476.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.